The NCCN Guidelines for NSCLC (version 7.2021) recommend molecular testing at the time of diagnosis with repeat biopsy or plasma testing to enable identification of genomic alterations in EGFR, ALK, ROS, BRAF, MET, and RET to guide the use of FDA-approved targeted therapies in the first-line advanced disease setting [2]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.